Northstar Neuroscience, Inc. Announces the Completion of Subject Enrollment and Randomization in the EVEREST Pivotal Trial for Upper Extremity Motor Recovery in Stroke Survivors

SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (NASDAQ: NSTR), a developer of medical devices for the treatment of neurological diseases and disorders, today announced the completion of subject enrollment and randomization in the EVEREST investigational study. EVEREST is Northstar’s pivotal trial of cortical stimulation for the treatment of hand/arm impairment in chronic stroke survivors.